ArticleEuropean journal of dentistry2026
Innovative Dentin Remineralization and Tubule Occlusion Using Titanium Dioxide-Doped Phosphate Glass and Diode Laser: An In Vitro Study.
Article in European journal of dentistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Titanium dioxide-doped phosphate glass (TDPG) is silica-free with enhanced chemical stability and ion release properties that could help in dentin remineralization. There is no evidence, however, regarding whether diode laser irradiation can enhance the clinical performance of TDPG paste in this regard. This article aims to evaluate the in vitro effectiveness of the combined use of TDPG paste and diode laser in occluding dentinal tubules, promoting dentin remineralization, and resisting acid challenge in comparison to a commercially available fluoride-containing NuPro prophy paste. Objectives: This article aims to evaluate the in vitro effectiveness of the combined use of TDPG paste and diode laser in occluding dentinal tubules, promoting dentin remineralization, and resisting acid challenge in comparison to a commercially available fluoride-containing NuPro prophy paste. Materials and Methods: Seventy mid-coronal dentin discs were prepared from extracted human premolar and molar teeth and randomly distributed into seven groups ( Results: SEM analysis showed incomplete tubules' occlusion with TDPG and a more uniform surface coverage with NuPro. Laser irradiation improved surface sealing for both materials. After the acidic challenge, NuPro + laser demonstrated better surface integrity, while TDPG + laser showed moderate resistance. RS revealed a significant reduction in the intensity of the phosphate peak after acid exposure in the NuPro groups, particularly with laser (45.8 and 48.9%, respectively), despite the initial high intensity in comparison to a reduction of 1.8% in the TDPG + laser group. TDPG-treated groups demonstrated increased phosphate and carbonate intensities post-acid challenge. Carbonate intensity followed similar trends, confirming greater acid resistance of TDPG formulations compared with NuPro. Conclusion: TDPG paste demonstrated a more chemically stable remineralization process, while NuPro prophy paste achieved better surface integrity after acidic challenge when used with a diode laser, but laser-induced damage in the form of microcracks was evident. The use of diode lasers may enhance the interaction and penetration of desensitizing agents, although compatibility with material composition must be improved for long-term performance. Clinical Significance: For immediate symptomatic relief of dentin hypersensitivity, a dual strategy using NuPro + laser is indicated. However, to achieve a sustained mineral reinforcement, the combined use of TDPG-based therapies with laser is recommended.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.